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Controlled release kineticsAbstract The aim of this study was to develop and optimize a nanoparticulate carrier based on
polymeric blends of cellulose acetate butyrate (CAB) and poly(vinyl pyrrolidone) (PVP) to enhance
dissolution proﬁle of an antiviral drug. These nanoparticles are studied by means of X-ray powder
diffraction, FTIR and DSC while the morphology evaluated using SEM analysis. Drug-loaded
nanoparticles were produced in spherical shape with sizes and encapsulation efﬁciency ranging from
322 to 434 nm and 50% to 70% respectively. The effects of different CAB/PVP ratios, concentra-
tion of drug and emulsiﬁer on the nanoparticle size, drug encapsulation and in vitro release were
studied in detail. In vitro release along with mechanism and kinetics were studied in different
pHs indicating that the release of drug from nanoparticles was pH-responsive. All the nanoparticles
displayed a slowed release pattern with the reduced burst release. The mechanism and kinetics of the
drug delivery system was also systematically studied using various models such as zero order, ﬁrst
order, Higuchi model and Korsmeyer–Peppas. The results indicate that the new CAB/PVP nano-
particles have a promising potential to serve as an antiviral controlled delivery system.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The importance of biocompatible and biodegradable polymers
is continuously increasing in pharmaceutical applications, to
prepare new controlled drug delivery systems (Raval et al.,
2014). For such systems size and morphology of the polymer
matrix assume an extremely important role in the drug release
and pharmacokinetics. Polymer physical blends are frequently
used as excipients in the pharmaceutical ﬁeld to obtain con-
trolled drug delivery systems due to their versatility (Karnichi
et al., 1995; Nerurkar et al., 2005; Patel and Patel, 2007; Rafﬁn
et al., 2007). Mixed polymer drug delivery systems must
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drug release proﬁle (Karavas et al., 2006). Broad ranges of sys-
tem characteristics and thus, drug release patterns can be pro-
vided simply varying the polymer blend ratio (Lecomte et al.,
2005), that could not be obtained by individual polymers (Sa-
hoo et al., 2010). This fact is demonstrated by the publication
of numerous patents and research papers and their utilization
in new products in the market place (Abbaspour et al., 2008;
Alkhatib and Sakr, 2003).
Recently, polymeric nanoparticles (NPs) are extensively
and intensively studied and are considered as one of the most
promising drug delivery systems (Duan et al., 2010). The deliv-
ery of pharmaceuticals can be improved by novel drug delivery
systems using therapeutic colloidal nanocarriers, including
polymeric nanoparticles (Ishiharaa et al., 2009). Several poly-
meric nanoparticulate systems have been prepared and charac-
terized based on both natural and synthetic biodegradable
polymers. The inherent shortcomings of conventional drug
delivery and the potential of nanoparticles as drug delivery sys-
tems have offered tremendous scope for researchers in this ﬁeld
and are fast moving from concept to reality. The nanoparticles
have the ability for both controlling the release and protecting
the loaded drug against its degradations; therefore, they may
improve the plasma half life of the drug (Mainardes et al.,
2010). All of these beneﬁts can contribute to the reduction of
dose and dosing frequency, thereby reducing the side effects
and improving the patient compliance (Bala et al., 2004).
Acyclovir (9-[2-hydroxyethoxymethyl]-9H-guanine, (ACY)
is an acyclic analog of the natural nucleoside 20-deoxyguano-
sine, most widely used drug for infections such as cutaneous
herpes, genital herpes, chicken pox, and varicella zoster infec-
tions. ACY has a short biological half life of 2–3 h and low
bioavailability of 10–20% (Naik and Raval, 2012). Due to a
short biological half-life, it is considered as an ideal candidate
for controlled drug delivery. Various approaches are made to
improve the concentration of ACY in the plasma over the ex-
tended period of time there by reducing the drug dosage and
unwanted toxic effects.
In this study, the objective was to design and characterize a
nanoparticulate carrier system for ACY to obtain a high con-
centration of the drug at infection site with prolonged resi-
dence providing a controlled release proﬁle, reduction of side
effects associated with systemic administration along with bet-
ter control over biodistribution. For this reason two polymers
with different properties such as hydrophobicity (cellulose ace-
tate butyrate (CAB)) and high hydrophilicity (poly(vinyl pyr-
rolidone) (PVP)) were selected. Several reports have
discussed the interaction of PVP with other polymers, surfac-
tants, and adsorbents (Sen and Yakar, 2001).
The nanoparticles were prepared by modiﬁed solvent evapo-
ration/extraction technique in combination with high speed
homogenizer and the main experimental factors inﬂuencing the
characteristics of nanoparticles were investigated to optimize
the preparation method. Poly vinyl alcohol (PVA) was used as
an emulsiﬁer. The main advantage of emulsiﬁer in process is
the instantaneous and reproducible formation of nanometric,
monodispersed nanospheres exhibiting a high drug loading
capacity (Derakhshandeh et al., 2007). Enhancement or retarda-
tion of ACY release rate from the nanoparticles can be achieved
by adjusting the ratio of two polymers; CAB and PVP, concen-
tration of the drug and emulsiﬁer. The physicochemical proper-
ties of the nanoparticles were characterized as well.2. Experimental
2.1. Materials
Acyclovir was received as a gift sample from Cadila Pharma-
ceuticals Ltd, (Ahmedabad, India). Cellulose acetate butyrate
of different molecular weights (12,000 Da), poly(vinyl pyrroli-
done) (MW about 3.6 · 105) and poly vinyl alcohol (MW
85,000, degree of hydrolysis 95%) were purchased from Al-
drich (Milwaukee, WI, USA). All chemicals used were of ana-
lytical grade and used as received. Double-distilled water was
used throughout the work.
2.2. Preparation of polymeric binary blend nanoparticles
Nanoparticles were prepared by solvent evaporation/extrac-
tion technique (Mu and Fenga, 2002) with slight modiﬁcation.
The objective of the present study was to understand the effect
of polymer blend composition, drug loading and emulsiﬁer
concentration on particle formation, particle morphology
and release behavior leading to lowest effective dose prepara-
tion of ACY. CAB and PVP were dissolved in organic solvent
mixture consisting of dichloromethane/acetone (9:1, v/v,
10 mL). ACY was dissolved in water (2 mL) and added in
the above solution. This mixture was sonicated using a micro-
tip probe sonicator set at 55W of energy output (XL 2002
Sonicator ultrasonic liquid processor) for 1 min to produce
the water-in-oil emulsion. The resulted solution was slowly
dropped into 50 ml PVA (0.5–1% w/v) as an external phase.
During this process, the mixture was homogenized using a high
speed homogenizer (CHG-15A, Daihan Scientiﬁc Co. Ltd,
Korea), at agitation speed of 20,000 rpm and kept on iced-
water bath. The formed water-in-oil-in-water (W/O/W) emul-
sion was gently stirred at room temperature for 3 h to evapo-
rate the organic solvents. The nanosuspensions were then
centrifuged at 14,000 rpm (Remi Elecktrotechnic Ltd, Vasai,
Maharashtra, India) 20 C for 20 min. Supernatants from
previous step were further centrifuged to ensure that all the
dispersed nanoparticles were collected. The collected nanopar-
ticles were washed (3 times) with distilled water using previ-
ously described centrifugation approach. The ﬁnal product
was stored in a vacuum desiccator at room temperature.
2.3. Determination of drug contents and loading efﬁciency
To determine drug contents, 5 mg of nanoparticles was dis-
solved in 5 ml of DCM and then 5 ml of deionized water
was added. This mixture was stirred magnetically for 6 h and
then 1 ml of water phase was taken to measure drug concentra-
tion. Absorbance of aqueous phase was measured at 252 nm
(Tao et al., 2009) using UV-spectrophotometer (UV-spectro-
photometer 1601, Shimadzu Co. Ltd, Japan). Drug contents
and loading efﬁciency were as follows:
% Drug loading ¼ Weight of drug in nanoparticles
Weight of nanoparticles
 
 100
ð1Þ
% Encapsulation efficiency ¼ % Drug loading
% Theoretical loading
 
 100
ð2Þ
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Particle size was measured by dynamic laser light scattering
model Halos–BF (Symantec, Germany). Size of the completely
dried nanoparticles of different formulations was measured by
dry sample technique using a dry sample adapter. The com-
pletely dried particles were placed on the sample tray with
an inbuilt vacuum under a compressed air system, which was
used to suspend the particles. The laser obscuration range
was maintained between 0.1 and 875 lm. The volume mean
diameter (VMD) was recorded. After the measurement of par-
ticle size of each sample, the dry sample adopter was cleaned
thoroughly to avoid cross contamination. Each batch was ana-
lyzed in triplicate, but average values were considered in data
analysis. The polydispersity index (PDI) which is a dimension-
less number indicating the width of the size distribution, hav-
ing a value between 0 and 1 (0 being for monodispersed
particles) was also obtained.
2.5. Particle morphology
The surface morphology and surface characteristics of samples
were studied by scanning electron microscopy (SEM). The
powder samples were dispersed in water, and were dropped
onto metal stubs and allowed to dry in air under ambient con-
ditions. Each sample was coated with gold under vacuum prior
to examination by SEM (JSM-5410, Jeol, Japan). The surface
of samples was scanned using a gaseous secondary electron
detector (working pressure: 0.8 torr, acceleration voltage:
30 kV, XL 30 (Philips, Eindhoven, Netherlands)).
2.6. Fourier transform infrared spectra
To investigate the possible chemical interactions between ACY
and the biodegradable polymers, the spectra were recorded for
CAB, PVP, placebo nanoparticles, drug-loaded nanoparticles
and pristine ACY using Fourier transform infrared spectros-
copy (FTIR; Spectrum GX, Perkin Elmer, Chicago, USA).
Polymer samples were crushed to make KBr pellets under a
hydraulic pressure of 300 kg/cm2. FTIR spectra were taken
in the wavelength region between 400 and 4000 cm1 and the
resolution of 0.15 cm1 at scan speed of 10 scan/s.
2.7. X-ray powder diffractogram
Pristine ACY, placebo and ACY-loaded nanoparticles were
evaluated by powder XRD technique to determine the crystal-
linity of drug. X-ray diffraction (XRD) patterns were obtained
using Philips X-ray diffractometer (X pert), with voltage of
40 kV, current of 40 mA and Cu a-radiation source in the
range of 3–40 of 2h with 1 s of scan time. All experiments were
performed at room temperature.2.8. Differential scanning calorimetry
Differential scanning calorimetry (DSC) curves were obtained
for CAB, PVP, placebo nanoparticle, drug-loaded nanoparti-
cle and pristine ACY with DSC-Pyris-1 (Perkin Elmer). The
analysis was performed with a heating range of 50–300 C
and at a rate of 10 C/min.2.9. Drug release study
To study in vitro drug release, the nanoparticles (all containing
5 mg of ACY) were placed in the vessels containing 100 ml of
phosphate buffer solution (PBS pH 1.2 and 7.4) as the dissolu-
tion medium. The vessels were incubated at 37 C with contin-
uous orbital mixing on a shaker (Lab-term, sic/incu shaker/01
Kuhner, Switzerland) at 50 rpm. The release medium was ex-
changed everyday to maintain the sink condition. At predeter-
mined time schedule, release medium was taken and
concentration of released drug was measured with UV-spectro-
photometer (SP-3000Plus, Tokyo) at 252 nm. The volume
withdrawn was replenished with an equal volume of fresh
and pre-warmed PBS 37 C to maintain the constant volume.
All experiments were done in triplicate.2.10. Release kinetics
Data obtained from in vitro drug release study, were ﬁtted to
various kinetic equations to ﬁnd out the mechanism and kinet-
ics of drug release from nanoparticles (Raval et al., 2012). The
model giving a correlation coefﬁcient close to unity was taken
as order of release. The kinetic equations used were zero order
equation, ﬁrst order equation and Higuchi model.
Qt ¼ k0t ð3Þ
where k0 is the zero-order rate constant expressed in units of
concentration/time and t is the time.
ln Qt ¼ ln Q0  k1 t ð4Þ
where k1 is the ﬁrst order constant.
Qt ¼ kht1=2 ð5Þ
where kh is the Higuchi constant reﬂecting the design variables
of the system.
The following plots were made; Qt vs. t (zero order kinetic
model), log(Q0Qt) vs. t (ﬁrst order kinetic model) and Qt vs.
square root of t (Higuchi model) (Higuchi, 1963), where Qt is
the total amount of drug released at time t and Q0 is the initial
amount of the drug present in the nanoparticles. The rate con-
stants were calculated for the respective models. Further, in or-
der to deﬁne a model which will represent a better ﬁt for the
formulation, the ﬁrst 60% drug release data were ﬁtted in
Korsmeyer–Peppas (Korsmeyer et al., 1983) equation.
Qt ¼ ktn ð6Þ
where k is the kinetic constant and n is the diffusion exponent,
a measure of the primary mechanism of drug release.3. Results and discussion
3.1. Drug loading, particle size and morphology
Size of particle can play a vital role as it can directly affect the
physical stability, biodistribution, cellular uptake and the drug
release. In general, the smaller the particle size, the better the
performance of the nanoparticles (Rieux et al., 2006). The size
of nanoparticles depends on the % PVP content, amount of
drug loaded in the polymer blended matrix, and concentration
of emulsiﬁer.
Table 1 Composition, encapsulation efﬁciency and size characteristics of CAB/PVP nanoformulations.
Batch No. CAB:PVP ACY%, w/w PVA%, w/v EE (%) Particle size (nm) ± SD PDI ± SD
B1 9:1 20 0.5 51.2 ± 2.2 418 ± 44 0.197 ± 0.073
B2 8:2 20 0.5 61.7 ± 1.4 345 ± 65 0.156 ± 0.081
B3 9:1 40 0.5 56.8 ± 2.4 434 ± 56 0.203 ± 0.054
B4 8:2 40 0.5 66.1 ± 1.8 396 ± 58 0.172 ± 0.061
B5 9:1 20 1.0 53.4 ± 1.2 388 ± 42 0.166 ± 0.083
B6 8:2 20 1.0 62.4 ± 1.4 322 ± 51 0.120 ± 0.053
B7 9:1 40 1.0 58.5 ± 1.6 421 ± 48 0.189 ± 0.044
B8 8:2 40 1.0 70.7 ± 1.3 352 ± 59 0.132 ± 0.072
Data represent mean value of triplicate ± standard deviation.
PDI stands for polydispersity index.
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434 nm. The results in Table 1 shows that the size of nanopar-
ticles decreases with the increase in the amount of PVP in the
polymer blended matrix. It is observed that particle size of B1
(10% (w/w), PVP) is larger than that of B2 (20% (w/w), PVP),
similarly the particle sizes of B3, B5 and B7 are larger than
those of B4, B6 and B8 formulations. This variation in size
was due to the fact that viscosity of polymer solution decreases
with higher amounts of PVP in the polymer blended matrix so,
smaller emulsion droplets were formed, resulting in smaller
nanoparticles. Thus as the hydrophilicity of the polymer in-
creases, the interaction amongst the polymer, oil phase and
aqueous phase changes accordingly.
Further, the results indicated that the particle size also de-
pended on amount of drug loaded. The formulations contain-
ing 20% drug (B1, B2, B5 and B6) produce lower particle
sizes than those containing 40% of drug (B3, B4, B7 and
B8). This can be explained by the fact that a greater amount
of drug results in a more viscous dispersed phase which
causes gathering of more of drug particles during the nano-
particle formation.
Another interesting observation is that particle size shows
dependence on the emulsiﬁer concentration. Particle size de-
creases with increasing extent of emulsiﬁer (Mainardes andFigure 1 Scanning electron micrographs of AcyEvangelista, 2005). The results in Table 1 shows that particle
size of B5, B6, B7 and B8 is smaller compared to B5 B2, B3
and B4. This is easy to understand: the emulsiﬁer remains at
the interface separating the oil and water phases. Smaller par-
ticles have a larger total surface area and thus need more emul-
siﬁer. Too much emulsiﬁer may result in particle aggregation
and too little emulsiﬁer would result in no nanoparticles for-
mation (Mu and Feng, 2003). SEM studies revealed a spherical
shape of resultant nanoparticles (Fig. 1).3.2. Encapsulation efﬁciency
It is important to achieve high encapsulation efﬁciency (EE),
for an effective formulation. The present study found that drug
encapsulation efﬁciency in nanoparticles was inﬂuenced by dif-
ferent experimental parameters such as drug–polymer ratio,
polymer blend composition and concentration of emulsiﬁer.
Results in Table 1 indicate that, % EE increases by increasing
the amount of PVP. This is due to the loss of hydrophilic
polymer from dispersed phase into aqueous continuous phase
because of its higher solubility in water. As a result encapsula-
tion efﬁciency could be enhanced by increasing the concentra-
tion of PVP in the formulation.clovir loaded CAB/PVP blend nanoparticles.
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drug loading, possibly being one of the most signiﬁcant factors.
As seen in Table 1, formulations containing a high amount of
drug exhibit higher values of EE. This can be explained by theFigure 2 FTIR of (a) CAB, (b) PVP, (c) placebo nanoparticle,fact that, when the drug loading was high, the more number
of drug particles were accumulated inside the free volume spaces
of the matrices and when the drug loading was low, the amount
of drug entrapped in the nanoparticles would decrease.(d) drug-loaded nanoparticle and (e) pristine acyclovir drug.
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tion of emulsiﬁer. As the concentration of emulsifying agent
increases, EE also increases due to the formation of a rigid net-
work, thereby retaining more drug particles during formula-
tion. Moreover, it could be observed that higher
concentrations of emulsiﬁer i.e. more than 1% cause aggrega-
tion of nanoparticles during the fabrication process where as
the shape of the nanoparticles obtained was not spherical.
3.3. Polymer–drug interaction analysis using FTIR spectroscopy
Interaction between the drug and polymers commonly leads to
identiﬁable changes in the FTIR patterns (Bhise et al., 2008).
FTIR spectra were compared to ﬁnd any change in frequency
of functional group in nanoparticles with respective functional
group of the drug. FTIR spectra of PVP, CAB, placebo nano-
particles, drug loaded nanoparticles and ACY are demon-
strated in Fig. 2.
FTIR spectrum of PVP shows the presence of stretching
adsorption peaks of –C‚O (1647.21 cm1), –C–N–
(1317.38 cm1), –C–H– (2951.09 cm1) and water (3649.32
cm1). FTIR spectrum of CAB, shows the presence of –C–H–
stretching vibrations (2937.59 cm1) and –O–H (3641.23
cm1). The placebo nanoparticles gave the characteristic peaks
of both PVP andCAB. FTIR spectrum ofACY, shows the pres-
ence of N–H (3439.08 cm1), –O–H (3296.35 cm1), C–H
(3130.47 cm1), C‚O (1691.57 cm1) stretching vibrations.
There is no signiﬁcant difference in characteristic peaks of
pristine drug and drug-loaded nanoparticles suggesting drug
stability during encapsulation process. This shows the absence
of any chemical interactions between drug and polymer.
3.4. X-ray diffraction studies
XRD is frequently used to analyze degree of sample crystallin-
ity. X-ray diffractograms of placebo nanoparticles, drug
loaded nanoparticles and pristine ACY were studied and are
demonstrated in Fig. 3. As indicated by X-ray examinations,
there was no clear peak in the X-ray diffractograms for theFigure 3 XRD spectra of (a) placebo nanoparticles, (b) drug-
loaded nanoparticles and (c) pristine acyclovir.amorphous polymer. The intact ACY manifested distinct
peaks that are characteristics of its crystalline nature.
However, distinct diffraction peaks have disappeared in the
ACY-loaded nanoparticles, but only peaks observed in
placebo matrix are observed signifying a drug amorphization
or its solvation in the amorphous carrier. XRD peak depends
on the crystal size, but in the present study, for all drug-loaded
matrices, characteristic peak of ACY was overlapped with the
noise of the polymer (Raval et al., 2014). This suggests that
even after encapsulation, blend matrix shows amorphous nat-
ure and hence, it is difﬁcult to study the crystallinity of ACY at
the detection limit of the crystal size. XRD data thus indicate
that drug is dispersed molecularly in the polymer matrix
(Jingou et al., 2011).
3.5. Differential scanning calorimetry
DSC has been extensively used calorimetric technique to char-
acterize the physical state of drug in the polymeric matrix.
Fig. 4 depicts the DSC thermogram of PVP, CAB, placebo
nanoparticles, drug loaded nanoparticles and pristine ACY.
CAB is mainly amorphous with a poor crystalline part which
shows a broad peak at 146 C. The thermogram of PVP
showed any characteristic peaks. Also, placebo nanoparticles
showed no peak and indicated the amorphous nature of carrier
particles. The DSC thermogram of ACY exhibited a single
sharp endothermic peak at 252.1 C corresponding to its melt-
ing transition temperature. This sharp endothermic peak indi-
cated that the intact ACY was in crystalline anhydrous state.
The thermogram of the drug loaded nanoparticles showed
no such characteristic peak, owing to the decreased crystallin-
ity in the formulations and/or drug solvation in the amorphous
carrier as well as solid state interaction induced by heating.
Thus, it revealed that the drug was uniformly dispersed at
the molecular level in nanoparticles.
DSC results demonstrated consistency with the ﬁndings ob-
tained from X-ray analysis. Concisely, the PXRD and DSC
studies veriﬁed a decrease of drug crystallinity in the
nanoparticles.Figure 4 The DSC thermogram of (a) CAB, (b) PVP, (c) placebo
nanoparticle, (d) drug-loaded nanoparticle and (e) pristine acy-
clovir drug.
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The drug delivery system was developed for the purpose of
bringing, up taking; retaining, releasing, activating, localizing
and targeting the drugs at the right time period, dose and place
(Sahoo et al., 2010; Rathbone et al., 1999). The biodegradable
polymer can contribute largely to this technology by adding
its own characters to the drugs. In the present study, a medium
molecular weight CAB was blended with PVP to prepare the
blend biodegradable polymer system. In vitro release experi-
ments of ACY from the polymer blend nanoparticles wereFigure 5 (a) Effect of polymer blend ratio on in vitro release for form
and B4 (20 wt.% PVP); (b) Effect of% drug loading on in vitro release f
wt.%), B6 (20 wt.%) and B8 (40 wt.%); (c) Effect of emulsiﬁer on in v
(1% PVA) and B7 (1% PVA) at 37 C.performed in simulated gastric (pH 1.2) conditions for ﬁrst 4 h
and continued in intestinal (pH 7.4) conditions. To avoid errone-
ous results due to sudden temperature changes, the dissolution
media (phosphate buffers) were gradually warmed to 37 C, at
which all the in vitro experiments were performed. Here,
in vitro release data are discussed in terms of effect of polymer
blend composition, drug loading and concentration of emulsi-
ﬁer. Average% cumulative release vs. time plots for drug-loaded
nanoparticles of all the formulations are displayed in Fig. 5(a–c),
respectively, to examine the effect of polymer blend composition,
drug loading and concentration of emulsiﬁer.ulations B1 (10 wt.% PVP), B2 (20 wt.% PVP), B3 (10 wt.% PVP)
or formulations B2 (20 wt.%), B4 (40 wt.%), B5 (25 wt.%), B7 (50
itro release for formulations B1 (0.5% PVA), B3 (0.5% PVA), B5
Table 2 Release rate constants kx, correlation coefﬁcients (R
2) and diffusion exponent (n) calculated after ﬁtting the release proﬁles
obtained using different mathematical models.
Formulation code Zero order First order Higuchi Korsmeyer–Peppas
R2 k0 R
2 k1 R
2 kh R
2 n
F1 0.942 1.207 0.975 0.043 0.989 4.29 0.985 0.442
F2 0.923 1.823 0.964 0.035 0.985 3.92 0.989 0.395
F3 0.953 1.703 0.984 0.028 0.994 4.73 0.983 0.419
F4 0.947 1.329 0.967 0.021 0.991 4.23 0.991 0.384
F5 0.926 1.027 0.951 0.027 0.990 4.51 0.989 0.425
F6 0.940 1.124 0.954 0.017 0.987 3.58 0.981 0.404
F7 0.958 1.106 0.987 0.010 0.996 3.34 0.992 0.389
F8 0.954 1.262 0.979 0.011 0.988 4.13 0.981 0.469
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The nature, morphology and properties of the polymers as well
as the blend composition in the systems are the important fac-
tors for controlling ACY release from the polymer blend nano-
particles. The effect of polymer blend ratio for formulations
B1, B2, B3 and B4 is displayed in Fig. 5(a).
The polymer blend formed remains stable in the dissolution
media and triggers the release of ACY drug showing slight
burst release at acidic pH, with controlled slow release in alka-
line pH media. Such initial burst release can be beneﬁcial to
improve the penetration of drug and to achieve the effective
plasma concentration after administration of ACY, while sus-
tained release delivers the drug over a prolonged period of
time. The observed burst effect was due to the fast nanoparti-
cle degradation, occurred due to the readily degradable PVP
polymer, which was then followed by a slower release from
the CAB sections (Nath et al., 2009). Another reason for burst
effect was the high solubility of drug in acidic pH. After 7 days
of slow release, a step functional release is observed with no
drug release, thereby showing a ﬁnal level off. The complete re-
lease of ACY was achieved between 5 and 7 days for all the
formulations.
Our investigations further revealed that the polymer blend
matrices with a higher content of hydrophilic PVP degraded
faster since degradation takes place more rapidly in PVP. So,
higher amounts of PVP, released higher amounts of drug
and vice versa. The results showed that % cumulative release
was higher for batches containing higher amounts of PVP in
polymer blend.
3.8. Effect of drug loading
The release proﬁles of drug from the blend nanoparticles at
different amounts of drug loadings are displayed in Fig. 5(b).
Results of the release data revealed that formulations contain-
ing the highest amount of drug (40%) displayed fast and high-
er release rates compared to those formulations containing a
small amount of drug loading. The increase in the drug content
causes increase in the amount of drug close to the surface and
in the core of nanoparticles. The increased initial burst effect is
caused by drug content which is closer to the surface of the
nanoparticle whereas the drug in the core of nanoparticles is
responsible for a prolonged drug release from the polymer
(Dhanalekshmi et al., 2010). When the amount of drug loadingis less, the drug release rate become slow, as a less number of
drug molecules have more free void spaces available to
transport.
3.9. Effect of concentration of emulsiﬁer
PVA appeared to be the most suitable emulsiﬁer in reducing
aggregation between nanoparticles which suspends immedi-
ately after formation. Nanoparticles were prepared at two dif-
ferent emulsiﬁer concentrations, i.e. 1% and 0.5%. As
displayed in Fig. 5c, formulation B1 exhibits higher release
than B5; similarly, B3 exhibits higher release than B7. Notice
that B5, B6, B7 and B8 contain higher concentrations of
PVA (1%) and hence, these are more rigid than B1, B2, B3
and B4.
3.10. Release kinetics
In order to determine the release model which best describes
the pattern of drug release, the in vitro release data were ﬁtted
to models representing zero-order, ﬁrst-order, and Higuchi’s
square root of time. The zero order release models describe,
the systems, where the rate of drug release is independent of
its concentration. The ﬁrst order release models, describe
the systems, where the rate of drug release is dependent of
its concentration. Higuchi model describes the rate of drug re-
lease from an insoluble polymer matrix as a square root of
time dependant process. To examine the mechanism of release
the data were ﬁtted to Korsmeyer–Peppas model. The release
constants were calculated from the slope of the appropriate
plots, and regression coefﬁcient (R2) was determined by linear
regression analysis and the results are tabulated in Table 2.
Based on the results, ACY release from nanoparticles fol-
lowed Higuchi equation and related correlation coefﬁcients
were better than both zero order and ﬁrst order kinetics. Thus
the ACY release from the nanoparticles was proportional to
square root of time. This indicates that the drug release is
controlled by diffusion of the drug through the pores for all
the formulations.
In all trials, drug release mechanism was studied by
applying Korsmeyer–Peppas model. According to Korsmeyer–
Peppas, a value of the exponent, n= 0.5, 0.5 < n< 1, n= 1.0
indicates Fickian diffusion, non-Fickian diffusion and purely
relaxation-controlled delivery which is referred to as Case II
transport, respectively. The results shown in Table 2. indicate
S176 D.R. Naik and J.P. Ravalthe values of diffusional exponent, n for the nanoparticles
lesser than 0.5 indicating a ﬁckian release (Budhian et al.,
2008).
4. Conclusion
Cellulose acetate butyrate is a hydrophobic biodegradable poly-
mer whereas poly(vinyl pyrrolidone) is a hydrophillic biopoly-
mer. The blending of the two polymers has been carried out
varying the proportion and it was found that the blend so ob-
tained proved to be a better drug carrier. SEM, Differential
scanning calorimetry, Fourier-transform infrared spectroscopy
and X-ray diffraction studies showed chemical stability and
intactness of entrapped drug in the nanoparticles. The study
demonstrated that it is possible to adjust the rate of drug release
by varying the polymer blend composition, drug loading and
concentration of emulsiﬁer to attain predictable release rates
from nanoparticles. According of these ﬁndings, formulation
of the ACY-loaded cellulose acetate butyrate/poly(vinyl pyrrol-
idone) binary blend nanoparticles was able to improve the phys-
icochemical characteristics of the drug and possibly will increase
the anti-retroviral effects of drug following its oral
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